To fasten the sensory block in upper limb surgery

Comparision of dexmedetomidine and nalbuphine as adjuvants to 0.25% bupivacaine in supraclavicular brachial plexus block for upper limb surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/08/044651

Enrollment

Registered

2022-08-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S599- Unspecified injury of elbow and forearm

Interventions

Intervention1: Group Dexmedetomidine: Patient to receive 15 ml of 0.5 % bupivacaine with 50mcg (0.5ml and dilution to 1ml with distilled water) dexmedetomidine and 14 ml normal saline Control Interven

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient concent 2.Age group-18 years to 60 years 3.Both sexs will be included 4.Weighing between 40-60kg 5.ASA physical status l and ll

Exclusion criteria

Exclusion criteria: 1.Patient refusal 2.Patient with known hypersensitivity to local anaesthetic agent 3.Patient having severe hypotension 4.Patient with cardiac disease 5.Patient with h/o conuvlsion 6.Patient with h/o peripheral sensorineural deficit 7.Injury,deformity or any pathology at injection site 8.Failed block

Design outcomes

Primary

Measure	Time frame
Onset and duration of sensory blockTimepoint: 24 hours	—

Secondary

Measure	Time frame
Onset and duration of motor block Quality of anaesthesia Duration of analgesia and time to rescue analgesia Level of sedation Side effects such as nausea and vomitingTimepoint: 24 hours	—

Countries

India

Contacts

Public ContactDr Praveen Kumar Tiwari

RIMS,Ranchi

drpkt80@gmail.com9661883797

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026